Results from the DELIVER study with Vyepti have been published in The Lancet Neurology.
H. Lundbeck A/S (Lundbeck) announces that the results from the DELIVER study have been recognized for their importance for the scientific and medical community.
The results from the clinical study with Vyepti (eptinezumab) were accepted for publication in the prestigious journal Lancet Neurology, one of the most cited medical journals within neurology. The DELIVER study results were published online on June 15, and the full paper can be accessed here: Lancet (thelancet.com).
The DELIVER study investigated the efficacy and safety of Vyepti 100 mg and 300 mg IV infusion in patients with chronic or episodic migraine who had experienced 2-4 previous preventive treatment failures due to lack of efficacy or intolerable side effects. The DELIVER study met its primary objective of demonstrating statistically significant superiority of Vyepti versus placebo in reducing the number of monthly migraine days (MMDs) over 12 weeks of treatment and it also achieved statistical significance on all key secondary outcome measures.
“These results contribute to the expanding body of evidence in support of migraine preventive treatments with anti-CGRP monoclonal antibodies in patients with previous preventive treatment failures to traditional oral medication. The key message from the study results, which is relevant for both physicians and patients, is that even after multiple treatment failures, there is still hope that patients can respond to this new class of anti-CGRP treatments”, says, Dr. Messoud Ashina, Professor of Neurology, and lead author on the DELIVER publication.
While 42% to 49% of patients who received Vyepti in the DELIVER study achieved a greater than 50% reduction in MMDs over 12 weeks, other studies with subcutaneously administered monoclonal antibodies targeting CGRP or its receptor (erenumab, fremanezumab, and galcanezumab) in patients with migraine and 2-4 previous preventive treatment failures migraine report that 30-38% of patients achieved a greater than 50% reduction in MMDs. In addition to the reduction in frequency of migraine days for patients treated with Vyepti, a larger reduction in the percentage of severe attacks for the remaining headache episodes compared to placebo was observed.
See- "Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase IIIb trial."- The Lancet Neurology. Vol. 21.No. 7p597–607.Published: July, 2022 Messoud Ashina,Michel Lanteri-Minet,Patricia Pozo-Rosich,Anders Ettrup,Cecilie Laurberg Christoffersen, Mette Krog Josiassen, and others.
Related news and insights
The Menarini Group and Radius Health, Inc. announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the FDA for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) who have HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.